Dr. Kevin D. Plancher appointed Lead Investigator for Episurf’s Episealer® IDE study
Episurf Medical AB (Nasdaq: EPIS B) announces that Dr. Kevin D. Plancher, MD, MPH of Plancher Orthopaedics & Sport Medicine, New York, has been appointed Lead Investigator for the company’s IDE clinical study, EPIC-Knee: Episealer® Knee System IDE Clinical Study. As Lead Investigator, Dr. Plancher will serve as a medical advisor to Episurf Medical and the other sites and investigators for any trial-related questions. Dr. Plancher will also be one of the surgeons performing surgeries in the clinical trial.
Dr. Plancher is a leading board-certified orthopaedic surgeon and sports medicine expert with extensive experience in treating knee cartilage injuries and an expert in minimally invasive procedures. Dr. Plancher is a Clinical Professor in Orthopaedics at Albert Einstein College of Medicine in New York, he is an active member of many prestigious national and international societies and serves on the Board of the American Academy of Orthopaedic Surgeons. Dr. Plancher graduated from Georgetown University School of Medicine, completed his residency at Harvard University's Combined Orthopaedic program and two post-graduate fellowships, one in hand and microvascular surgery (The Indiana Hand Center) and the other in sports medicine and reconstruction of the shoulder and knee (The Steadman Hawkins Clinic). Dr. Plancher has offices in New York City and Greenwich, Connecticut and is affiliated with the Lenox Hill Hospital, Stamford Hospital, Northern Westchester Hospital, and Mt. Sinai Beth Israel Medical Center. He is a team physician for the U.S. Ski & Snowboard Team and Long Island Lizards Lacrosse Team and serves as the League Physician for Major League Lacrosse.
“I am honored to assemble a thoughtful group of cartilage knee surgeons to undertake this clinical trial in the hope that patients will be able to return to sports and activities of daily living pain-free” says Dr. Kevin D. Plancher.
“We highly appreciate to have Dr. Plancher onboard as Lead Investigator in our IDE study. Dr. Plancher has huge experience within the field and has a genuine interest in research and in finding the right treatment solution for patients with focal cartilage lesions”, says Prof. Leif Ryd, Senior Medical Advisor at Episurf Medical.
“There are intense activities ongoing both in the US and in Europe to get additional sites ready to enroll patients to the IDE study, mainly related to clinical trial agreement completions and surgeon training. Having the Lead Investigator in place is a milestone, and we are very pleased with the outcome of that process. We are, of course, very happy for the opportunity to work with such an experienced surgeon as Dr. Plancher” says Pål Ryfors, CEO Episurf Medical.
For more information, please contact:
Pål Ryfors, CEO, Episurf Medical
Tel:+46 (0) 709 62 36 69
Email: pal.ryfors@episurf.com
About Episurf Medical
Episurf Medical is endeavoring to bring people with painful joint injuries a more active, healthier life through the availability of minimally invasive and individualised treatment alternatives. Episurf Medical’s Episealer® individualised implants and Epiguide® surgical drill guides are developed for treating localised cartilage injury in joints. Episurf Medical’s μiFidelity® system enables implants to be cost-efficiently tailored to each individual’s unique injury for the optimal fit and minimal intervention. Episurf Medical’s head office is in Stockholm, Sweden. Its share (EPIS B) is listed on Nasdaq Stockholm. For more information, go to the company’s website: www.episurf.com.
This information is information that Episurf Medical AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 10.30 CEST on 4 October 2019.
Tags: